0B68 Cristofanilli, Massimo - Thomas Jefferson University - Thomas Jefferson University

Massimo Cristofanilli, MD

Contact Dr. Cristofanilli

925 Chestnut Street
Suite 320A
Philadelphia, PA 19107

(215) 955-8874

Most Recent Peer-reviewed Publications

  1. Molecular characterization and targeted therapeutic approaches in breast cancer
  2. Cytometric characterization of Circulating Tumor Cells Captured by microfiltration and their correlation to the cellsearch® CTC test
  3. Inflammatory breast cancer management in the National Comprehensive Cancer Network: The disease, recurrence pattern, and outcome
  4. Cancer stem cells: implications for cancer therapy
  5. CCR5 receptor antagonists block metastasis to bone of v-Src oncogene-transformed metastatic prostate cancer cell lines
  6. TP53 mutations detected in circulating tumor cells present in the blood of metastatic triple negative breast cancer patients
  7. Circulating tumor cells as early predictors of metastatic spread in breast cancer patients with limited metastatic dissemination
  8. Response of an ERBB2-mutated inflammatory breast carcinoma to human epidermal growth factor receptor 2-targeted therapy
  9. AZD8931, an equipotent, reversible inhibitor of signaling by epidermal growth factor receptor (EGFR), HER2, and HER3: Preclinical activity in HER2 non-amplified inflammatory breast cancer models
  10. Emergence of constitutively active estrogen receptor-╬▒ mutations in pretreated advanced estrogen receptor-positive breast cancer
  11. Circulating giant macrophages as a potential biomarker of solid tumors
  12. Gene expression profiles of inflammatory breast cancer: Correlation with response to neoadjuvant chemotherapy and metastasis-free survival
  13. Circulating tumour cells: Telling the truth about metastasis
  14. Biomarkers and Therapeutic Targets in Inflammatory Breast Cancer (IBC)
  15. Survival of women with inflammatory breast cancer: A large population-based study
  16. Antitumor response of an ERBB2 amplified inflammatory breast carcinoma with EGFR mutation to the EGFR-TKI erlotinib
  17. Erythropoiesis stimulating agents and clinical outcomes of invasive breast cancer patients receiving cytotoxic chemotherapy
  18. PARP inhibitors for chemoprevention - Letter
  19. A comparison of epidemiology, biology, and prognosis of inflammatory breast cancer in Japanese and US populations
  20. Circulating breast tu 0164 mor cells exhibit dynamic changes in epithelial and mesenchymal composition